A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab
Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, and blood draws.
- Study Identifier: 832105
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required